Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30408374 | 1.00 | KIF11 (0.56) | KIF11DNMT1 | |
| SCHEMBL20202837 | 1.00 | KIF11 (0.56) | KIF11DNMT1 | |
| SCHEMBL18054925 | 0.89 | KIF11 (0.51) | KIF11DNMT1 | |
| SCHEMBL20202838 | 0.88 | KIF11 (0.50) | KIF11DNMT1 | |
| SCHEMBL20202847 | 0.88 | KIF11 (0.50) | KIF11DNMT1 | |
| SCHEMBL4406210 | 0.84 | KIF11 (0.54) | KIF11DNMT1 | |
| SCHEMBL2816104 | 0.84 | KIF11 (0.51) | KIF11DNMT1 | |
| SCHEMBL2546539 | 0.84 | KIF11 (0.54) | KIF11DNMT1 | |
| SCHEMBL5967574 | 0.84 | KIF11 (0.54) | KIF11DNMT1 | |
| SCHEMBL2816101 | 0.84 | KIF11 (0.51) | KIF11DNMT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4234537-A1 | REAGENT FOR MEASURING SKIN SENSITIZATION, COMPOUND, AND METHOD FOR MEASURING SKIN SENSITIZATION | FUJIFILM Corporation (JP) | 2023-08-30 | — | — | EP | disclosed |
| US-20230258569-A1 | REAGENT FOR MEASURING SKIN SENSITIZATION, COMPOUND, AND METHOD FOR MEASURING SKIN SENSITIZATION | FUJIFILM CORPORATION (JP) | 2023-08-17 | — | — | US | disclosed |
| WO-2022085762-A1 | REAGENT FOR MEASURING SKIN SENSITIZATION, COMPOUND, AND METHOD FOR MEASURING SKIN SENSITIZATION | 富士フイルム株式会社 | 2022-04-28 | — | — | WO | disclosed |
| US-20100210552-A1 | HUMAN GLUCAGON-LIKE PEPTIDE-1 MIMICS AND THEIR USE IN THE TREATMENT OF DIABETES AND RELATED CONDITIONS | BRISTOL-MYERS SQUIBB COMPANY | 2010-08-19 | — | — | US | disclosed |
| EP-2085403-A1 | PROCESS FOR PRODUCTION OF PEPTIDE THIOESTER | TOKAI UNIVERSITY EDUCATIONAL SYSTEM (JP) | 2009-08-05 | — | — | EP | disclosed |
| EP-0764149-B1 | NOVEL FARNESYL TRANSFERASE INHIBITORS, THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME | RHONE POULENC RORER SA (FR) | 1999-01-20 | — | — | EP | disclosed |
| US-5861529-A | ANTICANCER AGENTS | RHONE-POULENC RORER S.A. (FR) | 1999-01-19 | — | — | US | disclosed |
| EP-0764149-A1 | NOVEL FARNESYL TRANSFERASE INHIBITORS, THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME | Aventis Pharma S.A. (FR) | 1997-03-26 | — | — | EP | disclosed |
| WO-1995034535-A1 | NOVEL FARNESYL TRANSFERASE INHIBITORS, THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME | RHONE-POULENC RORER S.A. (FR) | 1995-12-21 | — | — | WO | disclosed |
| EP-0618221-A2 | Heterocyclic inhibitors of farnesyl protein transferase | BRISTOL-MYERS SQUIBB COMPANY (US) | 1994-10-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230258569-A1 | REAGENT FOR MEASURING SKIN SENSITIZATION, COMPOUND, AND METHOD FOR MEASURING SKIN SENSITIZATION | TST, CUTA, HNMT | KIF11 4229/4885DNMT1 246/4885 |
| US-20100210552-A1 | HUMAN GLUCAGON-LIKE PEPTIDE-1 MIMICS AND THEIR USE IN THE TREATMENT OF DIABETES AND RELATED CONDITIONS | GLP1R, IAPP, GIPR | KIF11 4499/4885DNMT1 4659/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.